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Background: Periprocedural hyperglycemia independently predicts mortality in patients (pts) undergoing percutaneous coronary intervention (PCI). 
Strategies to modify this risk factor have not been systematically evaluated
Methods: We randomized 328 pts to intensive or routine care. Pts with diabetes (n=160) were randomized to continue or hold their long-acting 
hypoglycemic medications prior to coronary angiography. The primary endpoint was glucose on procedural access. All pts were randomized to the 
Yale insulin infusion protocol (for glucose >140mg/dL on hourly assessment during procedure and for 6 hours after PCI) or standard care. The safety 
endpoint was hypoglycemia (asymptomatic glucose <50mg/dL or symptomatic glucose <75mg/dL)
Results: Diabetic pts who continued medications had lower glucose on procedural access and less need for insulin than the hold group. Glucose in 
non diabetics was lower than in diabetics and few needed insulin. There was 1 asymptomatic and 1 symptomatic hypoglycemic event corrected with 
glucose supplementation (both in diabetic continue group) and no serious adverse events
Conclusion: Routinely continuing long-acting hypoglycemic medications prior to coronary angiography helps achieve euglycemia during 
angiography and reduces the need for insulin to maintain euglycemia post-PCI, albeit with more frequent hypoglycemic events. Until an optimal 
periprocedural glucose target is elucidated, continuation of these medications should be considered as an option 
Diabetic patients (n=160)
Non-diabetic patients 
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Continue (n=80) Hold (n=80)
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Hold/Standard (n=40) p value - p value*
Glucose on 
procedural 
access, mg/dL**
113 [95-146] 134 [116-173] 0.0004
96 [185.5-
106]
0.0001
Insulin drip 
initiation, %
45 --- 70 --- 0.04 17
* versus diabetic continue group; **median [interquartile range]
